Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 12-week Phase IIa, Double-blind, Placebo-controlled, Randomized Study to Investigate the Efficacy and Safety of AZD7624 in COPD Patients With a History of Frequent Acute Exacerbations While on Maintenance Therapy

NCT02238483 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT02238483
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02238483 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 12-week Phase IIa, Double-blind, Placebo-controlled, Randomized Study to Investigate the Efficacy and Safety of AZD7624 in COPD Patients With a History of Frequent Acute Exacerbations While on Maintenance Therapy
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
October 28, 2014
Completion date
April 4, 2016
Enrollment
213 (actual)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

chronic obstructive pulmonary disease copd